Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Blanca Polo"'
Autor:
Ana Vagos Mata, Eduardo Espada, Daniela Alves, Blanca Polo, Maria João Costa, Conceição Lopes, João F. Lacerda, João Raposo
Publikováno v:
Cancer Medicine, Vol 10, Iss 24, Pp 8768-8776 (2021)
Abstract High‐dose methylprednisolone plus rituximab (R‐HDMP) is a useful treatment in chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients unfit for chemo‐immunotherapy and has proven its utility on the treatment of CLL/
Externí odkaz:
https://doaj.org/article/3dff904f36e1454c8eb294b3fe48a545
Autor:
Antonio Almeida, Francesca Pierdomenico, Blanca Polo Guerrero, Filipa Saraiva, Ana Montalvão, Jorge Coutinho, Mário Mariz, Teresa Melo, Maria João Santos, Alexandra Pereira, Nuno Cerveira
Publikováno v:
Acta Médica Portuguesa, Vol 32, Iss 7-8 (2019)
Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment. However, currently, the treatment-free remission concept is becoming an important goal in clinica
Externí odkaz:
https://doaj.org/article/92b0d287400c4f02b674866755108711
Autor:
Blanca Polo, Maria Joao Costa, Ana Vagos Mata, C. Lopes, João F. Lacerda, Daniela Alves, Eduardo Espada, João Raposo
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8768-8776 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8768-8776 (2021)
High‐dose methylprednisolone plus rituximab (R‐HDMP) is a useful treatment in chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients unfit for chemo‐immunotherapy and has proven its utility on the treatment of CLL/SLL compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb39f2319a8c256d465c5d21f9106a4a
https://doi.org/10.1002/cam4.4374
https://doi.org/10.1002/cam4.4374
Autor:
Nuno Cerveira, Antonio Almeida, Alexandra Pereira, Blanca Polo Guerrero, Francesca Pierdomenico, Ana Montalvão, Mário Mariz, Teresa Pinho e Melo, Filipa Saraiva, Maria José Santos, Jorge Coutinho
Publikováno v:
Acta Médica Portuguesa, Vol 32, Iss 7-8, Pp 550-557 (2019)
Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment. However, currently, the treatment-free remission concept is becoming an important goal in clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f60f578814d8b640dc646d810960467a
https://doi.org/10.20344/amp.11823
https://doi.org/10.20344/amp.11823
Publikováno v:
Seminars in Hematology. 55:215-222
Myeloproliferative neoplasms (MPN) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN are characterized by clonal proliferation of myeloid progenitors leading to erythrocytosis, thrombocytosis, or leu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ed95db1278379043fe696de62334548
https://doi.org/10.1053/j.seminhematol.2018.04.005
https://doi.org/10.1053/j.seminhematol.2018.04.005
Autor:
Maria Sanches, Blanca Polo, Daniela Alves, Ana Silva Martins, Raul Moreno, João Raposo, Cristina Ferreira, Luís Soares de Almeida
Publikováno v:
European Journal of Cancer. 156:S58
Background: The development of two different non-Hodgkin lymphomas in the same patient is an unlikely coincidence due to the low prevalence of each malignancy. However, a significantly increased risk of developing a second lymphoma was observed in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::946927536c1adf21cc85728c7593956d
https://doi.org/10.1016/s0959-8049(21)00734-6
https://doi.org/10.1016/s0959-8049(21)00734-6
Autor:
Raul Moreno, Graça Esteves, Helena Martins, Ana C. Alho, F. Lourenço, Blanca Polo, Conceição Garcia Martins, Joana Brioso Infante, S. Durão, João Raposo, Cristianne Confessor Castilho Lopes, Eduardo Espada, Joana Vieira, Manuel Neves, Maria Joao Costa, F. Velosa, J. Forjaz Lacerda, Sara Valle, Daniela Alves
Publikováno v:
HemaSphere. 3:954-955
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0de50715c7095976061964ee37627da0
https://doi.org/10.1097/01.hs9.0000566964.47272.3a
https://doi.org/10.1097/01.hs9.0000566964.47272.3a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Manuel Abecasis, Alberto Álvarez Larrán, Rosa Ayala Díaz, Santiago Barrio, Beatriz Bellosillo, Luigi Gugliotta, Juan Carlos Hernández Boluda, Jesús Honorato, Ana Kerguelen, Luz M. Martínez-Avilés, Joaquín Martínez López, Blanca Polo, Julián Sevilla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::971a16629a6ee3b46ea573f47cdb1b39
https://doi.org/10.1016/b978-84-9022-648-3.50003-9
https://doi.org/10.1016/b978-84-9022-648-3.50003-9
Autor:
Helena Martins, Rita Ferreira, Blanca Polo, Helena Proença, João F. Lacerda, Susana Mendes, Maria Joao Costa, C. Lopes, Lurdes Guerra, Sara Valle, Eduardo Espada, Daniela Alves, Carlos Martins, Carolina Viveiros, João Raposo, José A Carmo, Manuel Neves, Graça Esteves, Ana C. Alho, Inês Conde
Publikováno v:
Blood. 122:3150-3150
Introduction MM is characterized by the presence of a monoclonal immunoglobulin in the serum and/or urine, produced by malignant plasma cells. MM has a highly uncertain evolution and prognostic depending on age, stage and cytogenetic abnormalities. F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f98ebda54697f8de8e07f8a535e5565
https://doi.org/10.1182/blood.v122.21.3150.3150
https://doi.org/10.1182/blood.v122.21.3150.3150